论文部分内容阅读
目的观察益智平颤方治疗帕金森病合并轻度认知障碍的临床疗效及安全性。方法将80例患者随机分为治疗组和对照组,每组40例。两组均予西医常规疗法,治疗组同时加服益智平颤方。两组疗程均为3个月,观察帕金森病综合评分量表(UPDRSⅡ、UPDRSⅢ)、日常生活活动量表(ADL)、简易智能量表(MMSE)、蒙特利尔认知评估量表(MOCA)、帕金森神经心理痴呆评定量表(PANDA)的积分变化情况,并采用不良反应量表(TESS)观察不良反应情况。结果①与本组治疗前比较,治疗组治疗后ADL积分明显减少(P<0.05),对照组治疗后UPDRSⅡ、UPDRSⅢ积分增加(P<0.05);组间治疗后比较,治疗组UPDRSⅡ、UPDRSⅢ和ADL积分值均明显低于对照组(P<0.05)。②与本组治疗前比较,治疗组治疗后MMSE、Mo CA、PANDA积分均明显增加(P<0.05),对照组Mo CA积分明显减少(P<0.05);组间治疗后比较,治疗组各量表积分值均大于对照组(P<0.05)。③治疗组的不良反应发生率为7.5%,明显低于对照组的50.0%,TESS积分值少于对照组(P<0.05)。结论益智平颤方能明显提高帕金森病合并轻度认知障碍患者的认知水平,改善临床症状及生活质量,且安全性良好。
Objective To observe the clinical efficacy and safety of Yibibutongfang in treating Parkinson’s disease combined with mild cognitive impairment. Methods Eighty patients were randomly divided into treatment group and control group, 40 cases in each group. Both groups were treated with conventional Western medicine, while the treatment group added Yibibutongfang. The two groups were treated for 3 months. The UPDRS II, ADL, MMSE, MOCA, Parkinson’s neuropsychological dementia rating scale (PANDA) score changes, and the use of adverse reaction scale (TESS) observed adverse reactions. Results ①Compared with pretreatment group, ADL score of treatment group decreased significantly (P <0.05), UPDRS Ⅱ and UPDRS Ⅲ integral of control group increased (P <0.05); after treatment, UPDRS Ⅱ, UPDRS Ⅲ, ADL scores were significantly lower than the control group (P <0.05). ②Compared with before treatment, the scores of MMSE, Mo CA and PANDA in the treatment group were significantly increased (P <0.05), while the scores of Mo CA in the control group were significantly decreased (P <0.05); After treatment, Scores were larger than the control group (P <0.05). ③ The incidence of adverse reactions in the treatment group was 7.5%, which was significantly lower than that in the control group (50.0%). The TESS score was less than that in the control group (P <0.05). Conclusion Pu Yi Ping Chan can significantly improve the cognitive level of patients with Parkinson’s disease complicated with mild cognitive impairment, improve clinical symptoms and quality of life, and good safety.